Analysis

​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

By Jeff Overley · October 29, 2019, 9:06 PM EDT

A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. CEPHALON, INC.

Case Number

2:08-cv-02141

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

May 08, 2008

Case Title

KING DRUG COMPANY OF FLORENCE, INC vs. CEPHALON, INC., ET AL

Case Number

2:06-cv-01797

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

April 27, 2006

Case Title

OWENS v. PFIZER, INC., et al

Case Number

2:02-cv-01390

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

March 26, 2002

Case Title

In re Lidoderm Antitrust Litigation

Case Number

3:14-md-02521

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

April 03, 2014

Case Title

In Re: Aggrenox Antitrust Litigation

Case Number

3:14-md-02516

Court

Connecticut

Nature of Suit

Anti-Trust

Date Filed

April 03, 2014

Case Title

FEDERAL TRADE COMMISSION v. ABBVIE INC et al

Case Number

2:14-cv-05151

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

September 08, 2014

Case Title

In Re Namenda Direct Purchaser Antitrust Litigation

Case Number

1:15-cv-07488

Court

New York Southern

Nature of Suit

Anti-Trust

Date Filed

September 22, 2015

Case Title

Federal Trade Commission v. AbbVie Inc, et al

Case Number

18-2621

Court

Appellate - 3rd Circuit

Nature of Suit

1410 Antitrust

Date Filed

July 23, 2018

Recent Articles By Jeff